Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen versus tamoxifen + everolimus in aromatase inhibitor-resistant metastatic breast cancer
2006-004332-79Phase 2Completed
- Sponsor
- ARCAGY
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Tamoxifen alone with Tamoxifen + everolimus (2 arms). Primary endpoint: Clinical benefit rate at 24 weeks. Started Jun 2007; status: completed.
02
Drugs
tamoxifeneverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004332-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004332-79.